MX2012002161A - El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer. - Google Patents

El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.

Info

Publication number
MX2012002161A
MX2012002161A MX2012002161A MX2012002161A MX2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A MX 2012002161 A MX2012002161 A MX 2012002161A
Authority
MX
Mexico
Prior art keywords
cancer
hla
threating
patient
tnxb
Prior art date
Application number
MX2012002161A
Other languages
English (en)
Other versions
MX367580B (es
Inventor
Nan Bing
Linda Perry Briley
Laura R Budde
Charles J Cox
Colin F Spraggs
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607603&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002161(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of MX2012002161A publication Critical patent/MX2012002161A/es
Publication of MX367580B publication Critical patent/MX367580B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Se proporcionan los métodos para tratar a un humano que padece cáncer que comprende administrar al menos una dosis de lapatinib o una sal farmacéuticamente aceptable o composición de la misma a un paciente, en donde dicho paciente no tiene uno o más polimorfismos alélicos seleccionados del grupo de HLA-DQA1*0201, HLADQB1*2O2, y HLADRBI*0701; los pacientes también pueden estar libres de genotipos en TNXB; rs12153855 y/o rs17207923.
MX2012002161A 2009-08-21 2010-08-20 El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer. MX367580B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23594709P 2009-08-21 2009-08-21
US30756910P 2010-02-24 2010-02-24
PCT/US2010/046142 WO2011022633A2 (en) 2009-08-21 2010-08-20 Method of threating cancer

Publications (2)

Publication Number Publication Date
MX2012002161A true MX2012002161A (es) 2012-07-17
MX367580B MX367580B (es) 2019-08-27

Family

ID=43607603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002161A MX367580B (es) 2009-08-21 2010-08-20 El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.

Country Status (26)

Country Link
US (3) US20120156200A1 (es)
EP (1) EP2467140B1 (es)
JP (1) JP5876827B2 (es)
KR (1) KR101781658B1 (es)
CN (1) CN102770140B (es)
AU (2) AU2010284092A1 (es)
BR (1) BR112012003653A2 (es)
CA (2) CA3080511C (es)
CY (1) CY1118486T1 (es)
DK (1) DK2467140T3 (es)
EA (1) EA027959B1 (es)
ES (1) ES2589377T3 (es)
HR (1) HRP20161110T1 (es)
HU (1) HUE029098T2 (es)
IL (1) IL218230B (es)
LT (1) LT2467140T (es)
ME (1) ME02492B (es)
MX (1) MX367580B (es)
PL (1) PL2467140T3 (es)
PT (1) PT2467140T (es)
RS (1) RS55074B1 (es)
SG (2) SG178439A1 (es)
SI (1) SI2467140T1 (es)
SM (1) SMT201600296B (es)
WO (1) WO2011022633A2 (es)
ZA (1) ZA201201110B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011035540A1 (zh) 2009-09-28 2011-03-31 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-（取代苯胺基）喹唑啉衍生物
AU2013214254B2 (en) * 2012-01-31 2016-04-21 Novartis Ag Method of treating cancer
GB201403820D0 (en) * 2014-03-04 2014-04-16 Isis Innovation Assay
CN104293958B (zh) * 2014-10-16 2016-09-21 ***北京医院 一种预测强直性脊柱炎易感性的试剂盒和方法
JP2020502179A (ja) * 2016-12-14 2020-01-23 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． クロストリジウム・ディフィシレ毒素ｂを標的化する治療に対する応答に関連したヒト遺伝的マーカー

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US5871918A (en) 1996-06-20 1999-02-16 The University Of North Carolina At Chapel Hill Electrochemical detection of nucleic acid hybridization
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
WO1997040462A2 (en) 1996-04-19 1997-10-30 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
ES2186908T3 (es) 1996-07-13 2003-05-16 Glaxo Group Ltd Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas.
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
IL153111A0 (en) 2000-06-30 2003-06-24 Glaxo Group Ltd Quinazoline ditosylate salt compounds
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
WO2005121380A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham Corporation Predictive biomarkers in cancer therapy
JP2007117085A (ja) * 2005-09-28 2007-05-17 Genodive Pharma Kk 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法
JPWO2007099852A1 (ja) 2006-02-23 2009-07-16 国立大学法人金沢大学 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
WO2008070448A2 (en) * 2006-11-22 2008-06-12 Board Of Regents, The University Of Texas System Cancer-specific promoters
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
WO2008112903A2 (en) * 2007-03-13 2008-09-18 The Children's Hospital Of Philadelphia Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes

Also Published As

Publication number Publication date
US20170065590A1 (en) 2017-03-09
WO2011022633A3 (en) 2012-12-27
US20150231137A1 (en) 2015-08-20
HRP20161110T1 (hr) 2016-11-04
KR101781658B1 (ko) 2017-10-23
US9539257B2 (en) 2017-01-10
ES2589377T3 (es) 2016-11-14
SMT201600296B (it) 2016-11-10
CY1118486T1 (el) 2017-07-12
EP2467140B1 (en) 2016-06-01
LT2467140T (lt) 2016-09-12
EA027959B1 (ru) 2017-09-29
AU2014203270A1 (en) 2014-07-10
IL218230A0 (en) 2012-04-30
HUE029098T2 (en) 2017-02-28
CN102770140A (zh) 2012-11-07
IL218230B (en) 2019-02-28
ME02492B (me) 2017-02-20
ZA201201110B (en) 2012-10-31
BR112012003653A2 (pt) 2016-03-22
US10004742B2 (en) 2018-06-26
PL2467140T3 (pl) 2017-04-28
EA201270298A1 (ru) 2012-12-28
KR20120059564A (ko) 2012-06-08
CA2771699C (en) 2022-03-29
CA3080511A1 (en) 2011-02-24
EP2467140A4 (en) 2013-11-06
AU2010284092A1 (en) 2012-03-08
CA2771699A1 (en) 2011-02-24
JP2013502433A (ja) 2013-01-24
AU2014203270B2 (en) 2016-06-16
CN102770140B (zh) 2017-06-23
JP5876827B2 (ja) 2016-03-02
EP2467140A2 (en) 2012-06-27
PT2467140T (pt) 2016-08-30
SI2467140T1 (sl) 2016-10-28
US20120156200A1 (en) 2012-06-21
DK2467140T3 (en) 2016-09-05
MX367580B (es) 2019-08-27
WO2011022633A2 (en) 2011-02-24
CA3080511C (en) 2022-05-24
RS55074B1 (sr) 2016-12-30
SG10201405039VA (en) 2014-10-30
SG178439A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
IL189546A0 (en) Therapy for the treatment of disease
TW200612987A (en) Combination treatment for non-hematologic malignancies
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2011041632A3 (en) Combination therapies for the treatment of obesity
NZ604029A (en) Methods of treating bladder cancer
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
AU2010300611A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
WO2006086693A3 (en) Medical devices
WO2010045417A3 (en) Combination therapies for the treatment of obesity
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
WO2010151565A3 (en) Combination therapies for the treatment of obesity
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2012002161A (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
WO2010033884A3 (en) Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: NOVARTIS AG.*

FG Grant or registration